Respiratory Care Market, By Product Type (Nebulizers, Oxygen Concentrators , Polysomnography Devices, Positive airway pressure devices, Respiratory Consumables , and Others), By Indication (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Pneumonia, and Others), By End User (Hospitals, Ambulatory Surgical Centers, Clinics, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Apr 2024

Code : CMI6880

Pages :166

Formats :

Excel and PDF

Industry : Medical Devices

Market Concentration and Competitive Landscape

Respiratory Care Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Emergence of New Technologies

Another notable driver has been the emergence of new and advanced technologies in the respiratory care arena. Significant innovation is taking place in terms of devices, drug delivery mechanisms, and digital solutions for respiratory illnesses. On the device front, innovative portable oxygen concentrators are being introduced which are lightweight and can be carried anywhere. New generation ventilators are more automated and user-friendly. Connected nebulizers with mobile features are available. Wearable air purifiers are gaining popularity. The development of metered-dose inhalers (MDIs) with improved dose accuracy, breath-actuated inhalers, dry powder inhalers (DPIs) that eliminate the need for propellants, and smart inhalers with integrated sensors to monitor medication usage and inhalation technique. For instance, in February 2022, AstraZeneca, a Swedish multinational pharmaceutical and biotechnology company, and Honeywell, a U.S.-based publicly traded, multinational conglomerate corporation, announced that they are set to collaborate in the development of advanced respiratory inhalers (pressurized metered dose inhalers (pMDIs)), utilizing the propellant HFO-1234ze. This particular propellant exhibits a significantly low Global Warming Potential (GWP) when compared to the propellants currently employed in respiratory medications, with a potential reduction of up to 99.9%.

Key Players Insights